GLP-1 Medications Matched with Better Prediabetes Reversal and Lower Cardiovascular Risk
In a large electronic health record analysis presented at the American Heart Association’s Scientific Sessions 2026, GLP-1 receptor agonists were linked with stronger metabolic and cardiovascular outcomes than metformin among adults with prediabetes and obesity. The comparison matters because metformin remains the standard first-line medication for diabetes prevention, yet this study suggests a different class of glucose-lowering drugs may offer broader protection when treatment begins before frank Type 2 diabetes develops.
The cohort was sizable: 256,492 adults, average age 52, and 76% women. Roughly half received GLP-1-based medications — semaglutide, tirzepatide, liraglutide or dulaglutide — while the other half received metformin. Over an average follow-up of about three years, the medication groups diverged on several clinically important outcomes, including reversal to normal blood sugar, progression to Type 2 diabetes, death from any cause, and major cardiovascular events.
One result stood out immediately. Participants taking GLP-1 medications were about 1.5 times more likely to return from prediabetes to normal glycemic levels than those taking metformin.
Earlier Metabolic Improvement Came with Fewer Downstream Events
The pattern extended beyond glucose control. Compared with metformin, GLP-1 use was associated with a 31% lower risk of developing Type 2 diabetes and a 41% lower risk of death from any cause. The cardiovascular signal was also favorable: 15% fewer heart attacks, 20% fewer strokes, 25% fewer heart failure cases and 8% fewer cases of atrial fibrillation.
These findings fit the known biology of obesity-related cardiometabolic disease. Weight reduction can improve insulin sensitivity, lower blood pressure, reduce left ventricular filling pressures and ease the hemodynamic strain that drives heart failure and atrial fibrillation. GLP-1 therapies also influence appetite and satiety, which can translate into sustained weight loss and better glycemic control. In a population already living with excess weight and dysglycemia, those effects can stack in a way that changes risk across multiple organ systems, not just blood sugar alone.
Serra, a research fellow in the department of cardiovascular medicine at Mayo Clinic in Scottsdale, Arizona, described prediabetes as a stage where reversal remains possible. He argued that the findings may expand the case for considering GLP-1 medications earlier in selected patients rather than waiting until Type 2 diabetes appears. The clinical logic is straightforward: once diabetes is established, vascular and metabolic injury has often already advanced, while intervention at the prediabetes stage may interrupt that trajectory sooner.
Why the Comparison with Metformin Matters in Daily Practice
Metformin still occupies a central place in diabetes prevention because it is inexpensive, widely available and supported by long experience. Serra framed the issue as a shared decision-making conversation rather than a replacement strategy. For many patients, metformin remains entirely appropriate, especially when cost, access and tolerability are major concerns. For others, the weight-loss and cardiometabolic effects of GLP-1 therapy may make the treatment discussion more complex, particularly when obesity, rising glycemia and cardiovascular risk converge in the same patient.
Robert Eckel, professor of medicine emeritus at the University of Colorado Anschutz Medical Campus and a past volunteer president of the American Heart Association, said the benefits are biologically plausible because weight loss helps prevent progression from prediabetes to Type 2 diabetes. He also emphasized a practical constraint: these agents remain expensive and access can be uneven. In real-world prevention, the most effective medication is not always the one a patient can obtain consistently.
Lifestyle intervention remains the anchor of prediabetes care. Diet, physical activity and weight management still carry the most durable public health value, and medication choice should sit alongside those measures rather than replace them. In this study, the signal was strongest when looking at outcomes that often travel together in clinic: glucose normalization, diabetes prevention and cardiovascular event reduction.
Observational Data Pointed to Benefit, but the Design Leaves Gaps
Several features strengthen the credibility of the analysis. Investigators drew data from the TriNetX global multi-center electronic health record network across 104 institutions from 2010 to 2023. They also used matching methods to compare people with similar ages, comorbid conditions such as high blood pressure, sleep apnea or nicotine dependence, and similar medication histories. Those adjustments reduce, though do not eliminate, the chance that the results reflect baseline differences rather than treatment effects.
Even so, the study remains observational. It cannot prove causation. Diagnosis codes may miss or misclassify disease, prescription records do not guarantee medication adherence, and the analysis grouped all GLP-1-based drugs together, leaving agent-specific differences unresolved. Dose intensity and consistency of use were also unavailable, which matters because cardiometabolic responses often depend on exposure over time.
The study population itself raises another question. The average participant was middle-aged and predominantly female, and the results may not translate cleanly to every prediabetes population seen in practice. The event reductions are encouraging, but the analysis cannot determine whether the benefit came mainly from weight loss, direct metabolic effects, or some combination of both.
For now, the abstract points in one direction: in adults with prediabetes and obesity, GLP-1 medications were associated with better glycemic reversal and fewer heart and diabetes complications than metformin. The next step is not enthusiasm alone. A peer-reviewed manuscript, with more granular data on dosing, adherence and agent-specific performance, will be needed before these early findings can be folded into routine prevention strategy with confidence.